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Low-Cost Oral Delivery of Protein Drugs Bioencapsulated in Plant Cells
Abstract
Biopharmaceuticals made using current production systems are prohibitively expensive and are not
affordable for a large majority of the global population. The cost of protein drugs ($140 billion in 2013)
exceeds GDP of >75% of countries around the globe (Walsh, 2014), making them unaffordable in these
countries. The one-third of the global population that earns <$2 per day cannot afford any protein drugs.
This is because of their production in prohibitively expensive fermenters, purification, cold storage/
transportation, short shelf life and sterile delivery methods. Simpler methods of delivery such as oral
dosing could obviate much of the expense: however, oral delivery of protein drugs has been elusive for
decades because of their degradation in the digestive system, inability to cross the gut epithelium and
delivery to target cells/tissues.
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Biopharmaceuticals made using current production systems are prohibitively expensive and
are not affordable for a large majority of the global population. The cost of protein drugs
($140 billion in 2013) exceeds GDP of >75% of countries around the globe (Walsh, 2014),
making them unaffordable in these countries. The one-third of the global population that
earns <$2 per day cannot afford any protein drugs. This is because of their production in
prohibitively expensive fermenters, purification, cold storage/transportation, short shelf life
and sterile delivery methods. Simpler methods of delivery such as oral dosing could obviate
much of the expense: however, oral delivery of protein drugs has been elusive for decades
because of their degradation in the digestive system, inability to cross the gut epithelium and
delivery to target cells/tissues.

Mechanism of oral drug delivery
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An advantage of using plants to produce biologics is that the plant cell wall protects
expressed protein drugs from acids and enzymes in the stomach via bioencapsulation.
However, gut microbes have evolved to break down every component of plant cell walls—
so that when intact plant cells containing protein drugs reach the gut, commensal microbes
digest the cell walls and release the proteins. When tags (receptor binding proteins) are fused
to protein drugs, they efficiently cross the intestinal epithelium (largest mucosal area of the
body—1.8–2.7 m2) and are delivered to the circulatory or immune system (Jin and Daniell,
2015). The use of CTB and LTB as transmucosal carriers facilitates transportation of
conjugated proteins into circulation by binding to GM1 receptors (~15 000 per cell). After
crossing the epithelium, tags can be cleaved at engineered sites by proteases.
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Oral delivery of plant-made biopharmaceuticals currently advanced to the
clinic
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Recombinant glucocerebrosidase expressed in carrot cells via the nuclear genome and used
as a replacement therapy to treat Gaucher's disease is the first and most recent FDA
approved biopharmaceutical made in plant cells (Walsh, 2014). But this system still requires
expensive purification, cold storage/transportation and sterile delivery. However, recent
studies from the same group demonstrate significant potential for oral delivery of this
important drug (Shaaltiel et al., in this special issue). Glucocerebrosidase released from
carrot cells retained activity up to 120 min in simulated intestinal fluid mimicking fasting
conditions. When compared to intravenous injection of glucocerebrosidase with peak
activity in plasma after 30 min, an oral formulation showed an extended and slower release
of between 6 and 8 h; however, the efficiency of oral delivery of carrot cells was 10-fold
less. This may be due to the low-level expression of glucocerebrosidase via the carrot
nuclear genome.
One approach to increase transgene expression is to engineer the chloroplast genome: each
plant cell contains up to 10 000 copies of the chloroplast genome; therefore, transgenes
inserted into chloroplast genomes are expressed at high levels (up to 70% of the total leaf
protein). A wide range of proteins, ranging from very small antimicrobial peptides or
hormones to very large proteins encoded by bacterial, viral, fungal, animal and human
genes, have been successfully expressed in plant chloroplasts (Jin and Daniell, 2015). Most
importantly, therapeutic proteins are expressed at exceptionally high levels and lyophilized
plant cells can be stored for several months or years without a decrease in their functionality,
thereby eliminating costs of cold storage and transportation (Kwon et al., 2013).
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In a recent study, lettuce plants expressing clotting factor IX fused to cholera nontoxin
subunit B (CTB-FIX) were grown in the Fraunhofer research facility under growth
conditions that are directly translatable to its GMP pilot plant (Figure 1). Although only the
native human gene was expressed, up to ~1 mg/g CTB-FIX was observed in lyophilized
lettuce cells. CTB-FIX was stable, with proper folding, disulphide bonds and pentamer
assembly when stored for ~2 years at ambient temperature. Feeding lettuce cells to
haemophilia B mice delivered CTB-FIX efficiently to the gut immune system, induced
LAP+ regulatory T cells and suppressed inhibitor/IgE formation and anaphylaxis against
FIX. Ten-fold dose escalation studies showed similar tolerance efficacy facilitating oral
delivery of appropriate doses for patients of different age groups. Using the Fraunhofer
cGMP hydroponic system, ~870 kg fresh or 43.5 kg dry weight can be harvested per 1000
ft2 in 3–4 months yielding 24 000–36 000 doses for 20 kg paediatric patients, enabling the
first commercial development of an oral drug and addressing the prohibitively expensive
purification, cold storage/transportation and short shelf life of current protein drugs (Su et
al., 2015a,b). The concept of oral delivery of protein drugs expressed in plant cells is
illustrated in Figure 1. Also, recent studies on oral delivery of biopharmaceuticals and
atuoantigens produced in plant cells and their efficacy in animal testing are summarized in
Table 1 and discussed briefly below.
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Delivery of protein drugs across the blood–brain and blood–retinal barriers
(BBB/BRB)
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Alzheimer's disease (AD) is one of the major concerns of modern human society with an
anticipated increase in the affected population to 65.7 million by 2030. There is no cure or
treatment for this dreadful neurodegenerative disorder. Most of all, the tightly sealed blood–
brain barrier has hampered the translocation of drugs. In 2014, phase 3 trials with
bapineuzumab and solanezumab failed to meet primary endpoints in patients or to improve
cognitive and functional performance. Therefore, we developed a new approach to deliver
protein drugs across the BBB. MBP has been known to bind and degrade Aβ peptide and
inhibit Aβ fibril formation and it is a major structural component of the central nervous
system (CNS). CTB facilitated translocation of MBP through the intestinal epithelial
membrane to the circulation and across the BBB by binding to GM1 receptors at both sites.
In this study, bioencapsulated myelin basic protein (MBP) fused with CTB and expressed in
chloroplasts, when orally delivered, significantly reduced Aβ42 aggregates (Kohli et al.,
2014). The MBP level in brains of triple transgenic Alzheimer's disease (3 × TgAD) mice
was increased after oral delivery of lyophilized plant cells containing CTB-MBP, which was
accompanied by a reduction of the Aβ level and of Aβ42 aggregates in the hippocampus and
cortex. In addition, amyloid deposit was dramatically reduced in the inner retina of AD
mice, which indicated that MBP passed through the blood–retinal barrier.
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A parallel study demonstrated protein drug delivery across the BRB based on the
strengthening protective axis of the renin–angiotensin system (RAS). Uveitis, a sightthreatening intraocular inflammatory disorder which is caused by various factors, including
infectious agents, autoantigens and toxins, causes 5–15% of all cases of total blindness in
the United States. Ocular inflammation is associated with hyperactivity of the RAS in which
elevated angiotensin II (Ang II) acts as a potent pro-inflammatory effector. This deleterious
axis of RAS, composed of angiotensin converting enzyme (ACE)/AngII/angiotensin type I
receptor (AT1R), is counterbalanced by the protective axis of RAS involving ACE2/Ang(1-7)/Mas. Oral delivery of plant cells expressing CTB fused to ACE2 and Ang-(1-7)
increased their levels in the circulation and retina, enhanced systemic and local activity of
the protective axis of RAS, reduced endotoxin-induced uveitis (EIU) and dramatically
decreased cellular infiltration, retinal vasculitis, damage and folding in experimental
autoimmune uveoretinitis (Shil et al., 2014).

Regulation of metabolic disorders by orally delivered protein drugs
Author Manuscript

Cardiovascular homoeostasis is also controlled by RAS. The WHO projects that >23 million
people will die of cardiovascular disease annually by 2030. Pulmonary arterial hypertension
(PAH) is a fatal disease characterized by remodelling of the pulmonary vasculature,
resulting in elevated pulmonary vascular resistance and pulmonary artery pressure leading to
increased right ventricular (RV) failure and death. This is of critical importance, as the longterm treatment of PAH is currently limited by expense ($100,000–$200 000/year), side
effects and suboptimal survival of only 55% at 3 years. However, ACE2 in the lungs
converts AngII to Ang-(1-7), which stimulates the Mas receptor, resulting in
cardiopulmonary protective effects. Therefore, a decreased level of ACE2 in tissues and the
Plant Biotechnol J. Author manuscript; available in PMC 2016 February 28.
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circulation is linked to human lung diseases. When PH-induced rats were orally fed with
plant cells expressing ACE2 or Ang-(1-7), significant improvements in cardiopulmonary
structure and functions were observed in both the prevention and reversal protocols (Shenoy
et al., 2014). Not only was the elevated right ventricular systolic blood pressure decreased,
but the pulmonary blood flow was also improved. In addition, the authors found that oral
ACE2/Ang-(1-7) feeding restored right heart function and attenuated maladaptive
remodelling in diseased animals (Shenoy et al., 2014). Therefore, oral delivery of ACE2 or
Ang-(−17) is effective against PAH and is suitable for clinical trials towards providing
affordable PAH therapeutics.
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Diabetes was the direct cause of 1.5 million deaths worldwide in 2012. Type 2 diabetes is
responsible for 90% of the diabetic cases and affects a significant proportion of the global
population. As described in two separate studies, exendin-4 (EX4) has excellent properties
as an antidiabetes drug. Glucagon-like peptide-1 (GLP-1) is a peptide hormone secreted by
intestine cells that stimulates secretion of insulin from the pancreas, but this has a short life
because it is cleaved by dipeptidyl peptidase. EX4 is a DPP-resistant analogue of GLP-1,
with higher binding efficacy to the mammalian GLP-1 receptor present on the pancreas than
GLP-1 and functions as an effective agonist. EX4 modulates secretion of insulin to control
the blood glucose level in a glucose-dependent manner and has shown promising biological
activities in vivo for treating type 2 diabetes. EX4 is an injectable insulinotropic agent and
demonstrates appreciable antidiabetic effects in clinical use among patients with type 2
diabetes but requires cold storage and abdominal injections, decreasing patient compliance.
In two separate studies, EX4 fused to transferrin (Tf) or CTB was expressed via the nuclear
or chloroplast genome, to facilitate translocation of EX4 across the epithelial cells. Both
EX4 fusion proteins lowered the blood glucose level similarly to subcutaneous injections of
commercial EX4, but EX4 delivered orally without bioencapsulation in plant cells failed to
stimulate the pancreas to secrete insulin, due to its degradation in the stomach.

Oral tolerance induction using plant cells
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When the field of plant-made vaccines was pioneered by Prof. Charles Arntzen (see his
memoir in this issue), the primary goal was to develop cold chain-free vaccines to treat
global infectious diseases. This goal has not yet been realized, partly because of the inability
to induce immunity without priming the host immune system with adjuvants via injections
(see Chan and Daniell article in this issue for more details). In the presence of inflammatory
stimuli (adjuvants), local dendritic cells (DCs) become activated and present antigens for Tcell priming, locally and in the peripheral lymphoid tissues where DCs can migrate.
Immature DCs induce regulatory T cells (Tregs) that affect DC function and prevent stable
DCs–effector T-cell contact, thereby priming the immune response. This is a very different
scenario from the release of antigens into the gut immune system without priming, which is
geared towards an anti-inflammatory response. When antigens are presented to T cells by
immature DCs in the absence of inflammation or priming, they induce tolerance.
Furthermore, by secreting cytokines such as IL-10 or by direct cell-to-cell contact, Tregs
interfere with DC maturation, shifting DCs into tolerogenic function. Therefore, oral
delivery of autoantigens is ideal for induction of tolerance rather than immunity. We
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describe below two recent examples of induction of oral tolerance using autoantigens
expressed in plant chloroplasts.

Author Manuscript

Haemophilia is the X-linked bleeding disorder caused by mutations in clotting factor IX
(FIX, haemophilia B) or its cofactor, factor VIII (FVIII, haemophilia A). The current clinical
treatment for haemophilia patients is clotting factor replacement therapy via injection of
plasma-derived or recombinant factor concentrate. However, formation of inhibitory
antibodies (inhibitors) against FVIII or FIX seriously complicates treatment and increases
morbidity and mortality of the disease. Patients with high titres of inhibitors have to be
treated by immune tolerance induction (ITI) through administration of high-dose factor
concentrate for a long period of time. The cost of the clinical ITI treatment is highly
expensive. Furthermore, ~30% of the patients fail to respond to ITI treatment. We have
developed an oral tolerance induction protocol by expression of blood clotting factor VIII
(A1–A2 domains or heavy chain and C2 domain) fused to CTB in chloroplasts. After oral
delivery of plant cells to male haemophilia A mice twice per week for 2 months, they were
challenged with FVIII injections. Control mice fed with untransformed plant cells showed
very a high titre of inhibitors. In contrast, inhibitor formation against FVIII was significantly
suppressed (~sevenfold) in haemophilia A mice fed with FVIII-expressing plant cells. Most
importantly, plant-made FVIII antigen-mediated oral tolerance induction could also reverse
inhibitor formation (Sherman et al., 2014). These studies also identified a complex immune
regulatory mechanism behind prevention of inhibitors. Induced latency-associated peptide
expressing CD4+ regulatory T cells (CD4+CD25-LAP+) with increased expression levels of
interleukin-10 (IL-10), transforming growth factor-β (TGF-β) and conventional CD4+CD25+
regulatory T cells were demonstrated to be crucial for suppressing the formation of
pathogenic antibodies against clotting factors (Sherman et al., 2014).
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In parallel studies, a similar suppression of antibody titres was observed in another disease
model, facilitating broader application of this concept. Pompe disease (an autosomal
recessive lysosome disorder) is caused by mutations in the gene encoding acid alphaglucosidase (GAA). GAA is essential for the degradation of glycogen to glucose in
lysosomes. Accumulation of glycogen in lysosomes damages muscle and nerve cells,
causing a neuromuscular disease that impairs skeletal, cardiac and smooth muscles. Enzyme
replacement therapy (ERT) with recombinant human GAA (rhGAA) is currently the only
clinically available treatment. Without ERT, infantile-onset patients would not survive
beyond 2 years of age. More than 80% of severely affected patients have been shown to
form anti-GAA inhibitors, which not only neutralize the ERT but cause immunotoxicities.
Therefore, costly clinical ITI treatment is required for these severe patients. We developed a
cost-effective and efficient oral delivery protocol using plant chloroplast-made GAA
antigen. The N-terminal 410 amino acids of GAA were selected through T-cell epitope
mapping. Oral delivery of plant cells expressing CTB-GAA in chloroplasts, even at a 330fold lower dose than infused rhGAA, significantly suppressed GAA-specific inhibitory
antibody formation in Pompe mice with a threefold reduction in GAA-specific IgG1 titre
and significant suppression of GAA-specific IgG2a (Su et al., 2015a,b), further
demonstrating the high efficacy of oral tolerance induction by plant cells.
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Future perspectives
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Field trials were conducted a decade ago using transplastomic plants expressing
biopharmaceuticals or vaccine antigens. Chloroplast genomes are maternally inherited,
offering transgene containment via pollen (Jin and Daniell, 2015). Antigen expression in
leaves offers the opportunity to harvest them prior to the appearance of any reproductive
structures, facilitating complete transgene containment via both pollen and seeds. Most
importantly, a USDA-APHIS certification (dated 1/30/2013 to Dr. Daniell) stated that
transplastomic lines do not fit the definition of a regulated article under USDA-APHIS
regulations 7 CFR part 340, because there are no plant pest components, which should
further help in advancing this technology. In addition to potential regulatory advantages,
recent advances in developing novel therapeutic proteins in chloroplasts for urgent unmet
medical needs of several metabolic or genetic disorders, ability to express high levels of
proteins in edible plant cells, store lyophilized cells at ambient temperature for several
months/years without losing therapeutic efficacy, suitability for scale-up of production in
cGMP facilities and support of major pharmaceutical companies augur well for advancing
this low-cost and cold chain-free delivery system to lower the cost of protein drugs and
make them affordable to populations in great need.
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Figure 1.

Engineering plant cells to express protein drugs and lyophilization for oral delivery. Plant
cells are engineered by transforming either the nuclear or chloroplast genome. After a
selection process, plant cells are grown in sterile suspension cell bioreactors or in a
hydroponic cGMP facility. Harvested plant cells are lyophilized to facilitate long-term
storage and cold chain-free delivery. The lyophilized leaves are powdered and capsulated or
formulated in the form of juice for oral administration to treat or prevent human diseases.
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